LETRAFEM(Letrozole)
Therapeutic class: aromatase inhibitor
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy
- First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer
2.5 mg Tablets
2.5 mg:- A strip of 10 tablets- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
